Frisan T, Zhang Q J, Levitskaya J, Coram M, Kurilla M G, Masucci M G
Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.
Int J Cancer. 1996 Oct 9;68(2):251-8. doi: 10.1002/(SICI)1097-0215(19961009)68:2<251::AID-IJC19>3.0.CO;2-D.
Defects of antigen processing/presentation have been suggested to play a role in the escape of Burkitt's lymphoma (BL) from cytotoxic T lymphocyte (CTL)-mediated rejection. Impaired presentation of an immunodominant HLA A11-restricted epitope from the resident or recombinant vaccinia virus-expressed Epstein-Barr virus nuclear antigen (EBNA)4 was demonstrated in the EBV-positive E95B-BL28 and its EBV-negative parental BL28 cell lines. We have investigated whether this was due to (i) impaired production of the antigenic peptide, (ii) poor peptide translocation into the ER lumen or (iii) inefficient maturation and transport of the MHC-peptide complexes at the cell surface. The defect was not overcome by cytosolic expression of a pre-formed epitope, suggesting that presentation of EBNA4 is not limited by inefficient production of the antigenic peptide. BL28 expressed 5- to 10-fold lower levels of the transporter associated with antigen presentation (TAP) 1 and TAP2 proteins and behaved poorly in a streptolysin-O-mediated peptide translocation assay, whereas E95B-BL28 showed higher TAP expression and virtually normal transporter function. Up-regulation of HLA A11 and reconstitution of TAP activity by treatment with IFN-gamma did not restore presentation of the resident EBNA4 in E95SB-BL28 and did not enhance presentation of the vaccinia virus-expressed intact protein or preformed epitope. Efficient maturation of class I molecules to Endo H-resistant species was demonstrated in pulse-chase experiments. Taken together, our findings identify a previously uncharacterized defect of antigen presentation which appears to affect events occurring after proteasomal degradation but before TAP-dependent peptide transport and MHC class I assembly and maturation.
抗原加工/呈递缺陷被认为在伯基特淋巴瘤(BL)逃避细胞毒性T淋巴细胞(CTL)介导的排斥反应中起作用。在EBV阳性的E95B - BL28及其EBV阴性亲本BL28细胞系中,证实了来自常驻或重组痘苗病毒表达的爱泼斯坦 - 巴尔病毒核抗原(EBNA)4的免疫显性HLA A11限制性表位的呈递受损。我们研究了这是否是由于(i)抗原肽产生受损,(ii)肽向内质网腔的转运不良,或(iii)细胞表面MHC - 肽复合物的成熟和运输效率低下。预先形成的表位的胞质表达并未克服该缺陷,这表明EBNA4的呈递不受抗原肽产生效率低下的限制。BL28表达的与抗原呈递相关的转运蛋白(TAP)1和TAP2蛋白水平低5至10倍,并且在链球菌溶血素 - O介导的肽转运试验中表现不佳,而E95B - BL28显示出更高的TAP表达和几乎正常的转运蛋白功能。用IFN - γ处理上调HLA A11并重建TAP活性,并未恢复E95SB - BL28中常驻EBNA4的呈递,也未增强痘苗病毒表达的完整蛋白或预先形成的表位的呈递。在脉冲追踪实验中证实了I类分子向耐内切糖苷酶H物种的有效成熟。综上所述,我们的研究结果确定了一种以前未被表征的抗原呈递缺陷,该缺陷似乎影响蛋白酶体降解后但在TAP依赖性肽转运和MHC I类组装及成熟之前发生的事件。